Annovis Bio IncNYSE:ANVS
- LAST PRICE6.8200
- TODAY'S CHANGE (%)-0.1500 (-2.1521%)
- Bid / Lots6.8200/ 8
- Ask / Lots6.9100/ 8
- Open / Previous Close7.1000 / 6.9700
- Day Range
- 52 Week Range
- Volume146,517
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ANVS |
|---|---|---|
| 09:32 ET | 5358 | 7.1 |
| 09:33 ET | 5523 | 7 |
| 09:35 ET | 1250 | 7.04 |
| 09:37 ET | 700 | 7.11 |
| 09:39 ET | 2328 | 7.11 |
| 09:42 ET | 350 | 6.9923 |
| 09:44 ET | 3273 | 6.81 |
| 09:46 ET | 500 | 6.865 |
| 09:48 ET | 768 | 6.8 |
| 09:51 ET | 400 | 6.92 |
| 09:53 ET | 677 | 6.92 |
| 09:55 ET | 100 | 6.95 |
| 09:57 ET | 100 | 6.945 |
| 10:00 ET | 100 | 6.945 |
| 10:02 ET | 200 | 6.8966 |
| 10:08 ET | 431 | 6.87 |
| 10:09 ET | 2500 | 6.86 |
| 10:11 ET | 600 | 6.86 |
| 10:13 ET | 2933 | 6.81 |
| 10:15 ET | 2037 | 6.83 |
| 10:18 ET | 3450 | 6.84 |
| 10:20 ET | 1150 | 6.83 |
| 10:22 ET | 200 | 6.83 |
| 10:24 ET | 1300 | 6.845 |
| 10:26 ET | 1600 | 6.85 |
| 10:27 ET | 5200 | 6.8101 |
| 10:29 ET | 150 | 6.8681 |
| 10:31 ET | 317 | 6.86 |
| 10:33 ET | 2204 | 6.8 |
| 10:36 ET | 8291 | 6.819 |
| 10:38 ET | 120 | 6.822 |
| 10:42 ET | 100 | 6.815 |
| 10:44 ET | 200 | 6.8199 |
| 10:45 ET | 2641 | 6.77 |
| 10:47 ET | 950 | 6.81 |
| 10:49 ET | 503 | 6.8227 |
| 10:51 ET | 10397 | 6.88 |
| 10:54 ET | 330 | 6.82 |
| 10:58 ET | 200 | 6.81 |
| 11:02 ET | 100 | 6.84 |
| 11:03 ET | 1062 | 6.8 |
| 11:05 ET | 100 | 6.84 |
| 11:12 ET | 2400 | 6.79 |
| 11:14 ET | 902 | 6.8 |
| 11:23 ET | 400 | 6.85 |
| 11:25 ET | 650 | 6.84 |
| 11:32 ET | 100 | 6.95 |
| 11:34 ET | 1400 | 6.895 |
| 11:38 ET | 1000 | 6.9 |
| 11:43 ET | 200 | 6.9 |
| 11:45 ET | 450 | 6.9 |
| 11:50 ET | 1100 | 6.9 |
| 11:52 ET | 826 | 6.90273 |
| 11:56 ET | 600 | 6.9 |
| 12:01 ET | 1457 | 6.92 |
| 12:03 ET | 100 | 6.89 |
| 12:06 ET | 100 | 6.94 |
| 12:08 ET | 100 | 6.9399 |
| 12:10 ET | 700 | 6.94 |
| 12:15 ET | 100 | 6.945 |
| 12:19 ET | 1200 | 6.94 |
| 12:21 ET | 1095 | 6.95 |
| 12:24 ET | 1597 | 6.9455 |
| 12:26 ET | 210 | 6.8875 |
| 12:28 ET | 100 | 6.93 |
| 12:33 ET | 609 | 6.8741 |
| 12:35 ET | 230 | 6.87 |
| 12:37 ET | 200 | 6.88 |
| 12:46 ET | 232 | 6.865 |
| 12:48 ET | 300 | 6.87 |
| 12:50 ET | 100 | 6.89 |
| 12:51 ET | 918 | 6.89 |
| 12:53 ET | 100 | 6.89 |
| 12:55 ET | 200 | 6.89 |
| 01:00 ET | 500 | 6.88 |
| 01:02 ET | 800 | 6.86 |
| 01:06 ET | 400 | 6.84 |
| 01:08 ET | 140 | 6.79 |
| 01:13 ET | 100 | 6.825 |
| 01:20 ET | 2633 | 6.87 |
| 01:22 ET | 1100 | 6.8913 |
| 01:26 ET | 100 | 6.91 |
| 01:29 ET | 100 | 6.91 |
| 01:40 ET | 300 | 6.89 |
| 01:42 ET | 5000 | 6.9268 |
| 01:47 ET | 126 | 6.89 |
| 01:49 ET | 300 | 6.8804 |
| 01:51 ET | 2049 | 6.915 |
| 01:54 ET | 686 | 6.92 |
| 01:56 ET | 600 | 6.909 |
| 01:58 ET | 200 | 6.92 |
| 02:05 ET | 100 | 6.93 |
| 02:07 ET | 200 | 6.92 |
| 02:14 ET | 206 | 6.93 |
| 02:16 ET | 2000 | 6.915 |
| 02:21 ET | 800 | 6.9 |
| 02:23 ET | 100 | 6.9 |
| 02:25 ET | 340 | 6.875 |
| 02:30 ET | 100 | 6.88 |
| 02:38 ET | 225 | 6.87 |
| 02:41 ET | 8259 | 6.885 |
| 02:43 ET | 100 | 6.9 |
| 02:45 ET | 7340 | 6.82 |
Nov 12, 2024
Annovis Invited to Present at National Institute on Aging Workshop on Dementia with Lewy Bodies (DLB), from 8:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
8:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
Nov 11, 2024
DJ Annovis Bio Is Maintained at Buy by D. Boral Capital, from 5:16PM ET on Monday Nov 11, 2024 by Dow Jones
5:16PM ET on Monday Nov 11, 2024 by Dow Jones*DJ Annovis Bio Reports 3Q Fincl Results and Provides Business Update, from 8:02AM ET on Monday Nov 11, 2024 by Dow Jones
8:02AM ET on Monday Nov 11, 2024 by Dow JonesAnnovis Bio Reports Third Quarter Financial Results and Provides Business Update, from 8:00AM ET on Monday Nov 11, 2024 by Dow Jones
8:00AM ET on Monday Nov 11, 2024 by Dow JonesDJ Annovis Bio Price Target Maintained With a $30.00/Share by HC Wainwright & Co., from 7:39AM ET on Monday Nov 11, 2024 by Dow Jones
7:39AM ET on Monday Nov 11, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Annovis Bio Inc | 96.2M | -1.8x | --- |
Monopar Therapeutics Inc | 96.2M | -9.3x | --- |
Genenta Science SPA | 89.4M | -9.7x | --- |
Relmada Therapeutics Inc | 95.4M | -1.1x | --- |
Fibrobiologics Inc | 97.4M | -2.8x | --- |
Renovaro Inc | 94.4M | -0.6x | --- |
Company Information
Annovis Bio, Inc. is a clinical-stage drug platform company addressing neurodegeneration such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and other chronic neurodegenerative diseases. The Company is developing its lead product candidate, Buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. Its product candidate ANVS405 is an intravenous drug being developed for acute indications and focused on protecting the brain after traumatic brain injury (TBI) and/or stroke. ANVS405 is the same compound as Buntanetap, given in cases of acute head and brain trauma. ANVS301 is an orally administered drug being developed to increase cognitive capability in later stages of AD and dementia. ANVS301 is observed to improve memory and learning in very old rats by lowering the number of errors from six to three.
Contact Information
- Headquarters
- 101 LINDENWOOD DRIVE, SUITE 225MALVERN, PA, United States 19355
- Phone
- 484-875-3192
- Fax
- 610-727-4001
Executives
- Independent Chairman of the Board
- Michael Hoffman
- President, Chief Executive Officer, Founder, Interim Principal Financial Officer, Director
- Maria Maccecchini
- Independent Director
- Claudine Bruck
- Independent Director
- Reid Mccarthy
- Independent Director
- Mark White
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $96.2M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 13.8M |
Annovis Bio Inc does not pay a dividend. | |
Beta | 1.63 |
EPS | $-3.76 |
Book Value | $-0.74 |
P/E Ratio | -1.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
